

# Wen-Jen Hwu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7982288/publications.pdf>

Version: 2024-02-01

46  
papers

12,076  
citations

218677

26  
h-index

214800

47  
g-index

49  
all docs

49  
docs citations

49  
times ranked

18956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	27.0	3,128
2	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
3	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	28.9	1,515
4	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
5	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
6	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
7	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	27.8	269
8	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	10.7	233
9	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
10	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
11	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	1.3	186
12	Beyond BRAF V600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
13	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018, 3, .	5.0	107
14	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
15	Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma. <i>JAMA Ophthalmology</i> , 2018, 136, 1236.	2.5	74
16	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	2.8	69
17	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
18	Cranial Electrotherapy Stimulation for the Management of Depression, Anxiety, Sleep Disturbance, and Pain in Patients With Advanced Cancer: A Preliminary Study. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 198-206.	1.2	48

#	ARTICLE	IF	CITATIONS
19	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	3.4	46
20	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	4.5	45
21	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	2.0	43
22	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
23	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	2.6	31
24	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2019, 9, 8332-8343.	10.0	31
25	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
26	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	4.2	29
27	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	7.0	27
28	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 504-507.	1.3	25
29	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	3.7	23
30	Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. <i>Discovery Medicine</i> , 2015, 19, 393-401.	0.5	21
31	Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. <i>Archives of Medical Research</i> , 2020, 51, 827-838.	3.3	17
32	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	12.8	15
33	The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 933-940.	2.4	14
34	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	4.1	10
35	BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 313-321.	0.6	10
36	Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. <i>Melanoma Research</i> , 2010, 20, 501-506.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202.	4.1	9
38	Prognostic significance of acral lentiginous histologic type in T1 melanoma. <i>Modern Pathology</i> , 2021, 34, 572-583.	5.5	8
39	Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 943-952.	2.5	8
40	TERT amplification but not activation of canonical Wnt/ $\beta$ -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074.	5.5	6
41	Aberrant expression of FLI-1 in melanoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 790-793.	1.3	5
42	Treatment of BRAF-mutated advanced cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 28.	1.2	5
43	Desmoplastic Melanoma of the Periorbital Region. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e48-e52.	0.8	4
44	Management of melanoma brain metastases. <i>Melanoma Management</i> , 2015, 2, 225-239.	0.5	2
45	Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update. <i>Discovery Medicine</i> , 2018, 25, 31-40.	0.5	2
46	Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 357-364.	0.9	0